Media Availability: Low-Fat Dietary Pattern May Lower Risk of Ovarian Cancer -- The WHI Dietary Modification TrialOctober 10, 2007A diet low in fat could reduce the risk of ovarian cancer in healthy postmenopausal women, according to new results from the Women's Health Initiative (WHI) Dietary Modification Trial. Researchers found that after four years, women who decreased the amount of dietary fat they consumed were 40 percent less likely to develop ovarian cancer than women who followed normal dietary patterns. As expected, no effect was found during the first four years because preventive benefits on cancer often take many years to develop. Ovarian cancer affects about 1 in 60 U.S. women in their lifetimes and has the highest mortality of all cancers of the female reproductive system. "Low-Fat Dietary Pattern and Invasive Cancer Incidence: Further Results from the Women's Health Initiative Dietary Modification Trial," is published online October 9 by the Journal of the National Cancer Institute. The WHI Dietary Modification Trial was conducted in 40 clinical centers throughout the United States and is funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. The WHI Dietary Modification clinical trial followed 48,835 healthy, postmenopausal women for an average of 8.1 years to test whether a low-fat diet would reduce the risk of cancer and cardiovascular disease. Nearly 20,000 women in the intervention group were counseled to decrease fat intake to 20 percent of calories and to replace calories from fat with calories from vegetables, fruits, and grains. The control group (nearly 30,000 women) received diet-related education materials only.
Women in both groups started with average consumption of more than 35 percent of calories from fat when they joined the study. By the end of the first year, the low-fat diet group reduced average total fat intakes to 24 percent of calories from fat, about 11 percent less than the women in the usual diet group. By the end of the study, women in the low-fat diet group averaged 29 percent calories from fat, compared to 37 percent calories from fat in the usual diet group. The low-fat diet group also increased their consumption of vegetables, fruits, and grains. Researchers found that women who started with the highest fat intake and who reduced their fat intake the most during the study lowered their risk of ovarian cancer the most. In addition, although no effect on rates of endometrial cancer were found, the new results suggest a small reduction in overall risk of cancer among the women who ate less fat, but this finding was not statistically significant. In the study's primary findings published in the February 8, 2006, issue of the Journal of the American Medical Association, women in the low-fat diet group had a tendency toward reduced risk of breast cancer, heart disease, and stroke, and no reduction in risk of colorectal cancer. The overall 9 percent reduction in breast cancer was not statistically significant; however, like the results for ovarian cancer, the study found that women who started with the highest fat intake lowered their risk of breast cancer more markedly. The WHI is the most comprehensive study to date of the causes and prevention of the major diseases affecting the health of older women. Over 15 years, the study's findings on heart disease, breast and colorectal cancer, and osteoporosis have stimulated many changes in clinical practice. The WHI is also one of the largest studies of its kind ever undertaken in the United States and is considered a model for future studies of women's health. This study of low-fat dietary pattern is one of the three randomized clinical trials that make up the WHI. The others included trials of hormone therapy (estrogen plus progestin and estrogen alone). Both trials were stopped early because of increased risk of diseases like stroke, blood clots, and breast cancer, and because the hormones failed to reduce risk of heart disease. The third clinical trial studied the effects of calcium and Vitamin D supplementation on osteoporosis-related bone fractures and on colorectal cancer. As reported in February 2006, the study found that calcium and vitamin D supplements provide a modest benefit in preserving bone mass and prevent hip fractures in certain groups of healthy postmenopausal women, especially those over age 60, but do not prevent other types of fractures or colorectal cancer. WHI Project Officer Jacques Rossouw, M.D., of NHLBI and Leslie G. Ford, M.D., associate director for clinical research in the National Cancer Institute's Division of Cancer Prevention, are available for comment. To schedule interviews, contact the NHLBI Communications Office at 301-496-4236 or at nhlbi_news@nhlbi.nih.gov, or the NCI Office of Media Relations at (301) 496-6641 or at ncipressofficers@mail.nih.gov. Resources: * For selected findings from the WHI Dietary Modification Trial, http://www.nhlbi.nih.gov/whi/diet_mod.htm * For more on the Women's Health Initiative, see http://www.nhlbi.nih.gov/whi/ * For information on ovarian cancer, see http://www.cancer.gov/cancertopics/types/ovarian * For current recommendations on eating patterns for heart health, see Your Guide to a Healthy Heart book at http://www.nhlbi.nih.gov/health/public/heart/other/your_guide/healthyheart.htm. * For information on eating for general health, see http://www.health.gov/dietaryguidelines/dga2005/recommendations.htm NHLBI is part of the National Institutes of Health (NIH), the Federal Government's primary agency for biomedical and behavioral research. NHLBI press releases and fact sheets, including information on the Women's Health Initiative and on overweight and obesity can be found online at www.nhlbi.nih.gov. The National Cancer Institute (NCI), part of the National Institutes of Health in Bethesda, Maryland, coordinates the Nation's research program on cancer prevention, detection, diagnosis, treatment, rehabilitation, and control. For more information, visit www.cancer.gov. The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov. The National Institutes of Health | |||||||||||||||||||||
|
Related Ovarian Cancer News Articles Variation of normal protein could be key to resistance to common cancer drug Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug. New method to overcome multiple drug resistant diseases developed by Stanford researchers Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them. How chemo kills tumours: research to reduce side effects Dr Stephen Taylor and Karen Gascoigne at the University's Faculty of Life Sciences have taken a new systematic approach to studying anti-mitotic drugs, which are used extensively for breast or ovarian cancer in the UK. American Cancer Society study finds high use of complementary methods among cancer survivors A new study from researchers at the American Cancer Society finds many cancer patients use complementary and alternative methods, most often prayer, relaxation, supplements, meditation, and massage. Study finds that significant proportion of men told wife's cancer was incurable late or not at all A study conducted in Sweden found that more than 40 percent of widowers in that country whose wives died from cancer four or five years earlier reported they were either never told that their spouse's cancer was incurable, or they heard this information during the last week of her life. Symptom screening plus a simple blood test improves early detection of ovarian cancer Women's reports of persistent, recent-onset symptoms linked to ovarian cancer - abdominal or pelvic pain, difficulty eating or feeling full quickly and abdominal bloating - when combined with the CA125 blood test may improve the early detection of ovarian cancer by 20 percent. PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer Combined positron emission tomography (PET) and computed tomography (CT) scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery. Glypican-3 gene function in regulating body size helps inform novel cancer treatments In a leading study that has implications for the development of novel therapies for a number of breast, lung and ovarian cancers that have lost the expression of a gene called glypican-3 (GPC3), Sunnybrook researchers have discovered how the loss of the GPC3 gene induces overgrowth through certain growth factors such as Sonic Hedgehog which stimulate cancer growth. Researchers identify new cell targets for preventing growth of breast and other tumors Researchers at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have discovered new targets for cancer treatment aimed at blocking a key step in tumor progression. Researchers identify new cell targets for preventing growth of breast and other tumors Researchers at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have discovered new targets for cancer treatment aimed at blocking a key step in tumor progression. More Ovarian Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||